BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Avila Therapeutics Completes Dosing of First Patient Cohort in Phase 1b Clinical Study of AVL-292, a Selective Bruton's Tyrosine Kinase Inhibitor for the Treatment of B Cell Cancers


9/14/2011 9:04:09 AM

BEDFORD, Mass.--(BUSINESS WIRE)--Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has completed 28 days of dosing of the first cohort of patients in its Phase 1b clinical trial of AVL-292 and is now advancing to the second dose cohort in this trial. The trial is being conducted in patients with B cell cancer malignancies including B-cell Non-Hodgkin Lymphoma (B-NHL) and Chronic Lymphocytic Leukemia (CLL). AVL-292 is a novel, orally available, and highly selective covalent inhibitor that inhibits Bruton’s tyrosine kinase (Btk). In two completed Phase 1a studies in healthy volunteers, AVL-292 demonstrated a favorable safety, tolerability, and pharmacokinetic profile.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES